Search results for: hip OA

What Does the ‘New Normal’ Look Like? A Q&A with Jay Mehta, MD

Mary Choy, PharmD, BCGP, FASHP | November 24, 2020

With his clinic resuming in-person visits, Jay Mehta, MD, says his patients and staff have proved remarkably adaptable, embracing telemedicine during the early days of the pandemic and now facemasks during appointments.

Osteoporosis Experts Discuss Bisphosphonate Holidays

Susan Bernstein | November 24, 2020

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020

Elizabeth (Blair) Solow, MD | November 23, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered …

ACR Introduces Draft Guideline for RA Management

Jason Liebowitz, MD, FACR | November 23, 2020

Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.

After the 2020 Election, What’s in Store for Rheumatology Advocacy?

ACR Advocacy Staff | November 22, 2020

Despite high voter turnout and many new faces entering Congress, minimal power shifts in most levels of government will have implications for the ACR’s advocacy agenda in 2021.

Deborah Dyett Desir, MD, Joins ACR Executive Committee as Secretary

Kurt Ullman | November 22, 2020

To her new role as ACR Secretary, Dr. Desir brings extensive experience in both private practice and academic medicine, more than a decade of volunteer leadership experience in the ACR and a deep commitment to service.

ACR Advances Rheumatology Positions in American Medical Association Policies

From the College | November 22, 2020

At the American Medical Association House of Delegates Special Meeting held Nov. 13–17, 2020, the ACR’s delegation successfully led an effort to update AMA policies on home infusion and copay accumulators.

Anti-TNF Treatment Trial Encouraging for High-Risk APS Pregnancies

Thomas R. Collins | November 19, 2020

Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.

Food for Thought: On Eating & Inflammation in Rheumatic Disease

Susan Bernstein | November 14, 2020

Certain nutrients or dietary patterns may affect inflammation and rheumatic disease risk in certain populations. Recommended nutrients include omega-3 fatty acids found in fish, poultry or nuts. Following a Mediterranean or standard Western diet may affect RA risk too.

Can We Predict & Prevent Pregnancy Complications in Patients with Lupus & APS?

Thomas R. Collins | November 13, 2020

ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said. In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to…